<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Cyclosporine (ciclosporin) (ophthalmic): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Cyclosporine (ciclosporin) (ophthalmic): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Cyclosporine (ciclosporin) (ophthalmic): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11643" href="/d/html/11643.html" rel="external">see "Cyclosporine (ciclosporin) (ophthalmic): Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="15961" href="/d/html/15961.html" rel="external">see "Cyclosporine (ciclosporin) (ophthalmic): Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F8012533"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Cequa;</li>
<li>Restasis;</li>
<li>Restasis MultiDose;</li>
<li>Verkazia;</li>
<li>Vevye</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52869097"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Cequa;</li>
<li>Restasis;</li>
<li>Restasis MultiDose;</li>
<li>TEVA-CycloSPORINE;</li>
<li>Verkazia</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F8105271"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Calcineurin Inhibitor;</li>
<li>
                        Immunosuppressant Agent</li></ul></div>
<div class="block doa drugH1Div" id="F8012638"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4993b190-760b-4de4-b033-07a2e036dc6e">Dry eye disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Dry eye disease (Cequa, Restasis, Vevye): Ophthalmic:</b> Instill 1 drop in each eye twice daily (~12 hours apart).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f5f7cc6a-66f2-472a-81a0-39f6fc7acf4d">Vernal keratoconjunctivitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Vernal</b>
<b>keratoconjunctivitis (Verkazia): Ophthalmic:</b> Instill 1 drop in each affected eye 4 times daily (morning, noon, afternoon, and evening) until signs/symptoms resolve. Treatment may be reinitiated if there is a recurrence.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Missed</i>
<i> dose:</i> If a dose is missed, treatment should be continued as normal, at the next scheduled administration.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990139"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. However, dosage adjustment unlikely due to low systemic absorption.</p></div>
<div class="block doha drugH1Div" id="F50987459"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. However, dosage adjustment unlikely due to low systemic absorption.</p></div>
<div class="block doe drugH1Div" id="F8012639"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F8105272"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="15961" href="/d/html/15961.html" rel="external">see "Cyclosporine (ciclosporin) (ophthalmic): Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3b119b1c-0f39-4028-9445-a1bad86d2fe2">Keratoconjunctivitis sicca</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Keratoconjunctivitis sicca:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Emulsion 0.05% (eg, Restasis): Adolescents ≥16 years: Ophthalmic: Instill 1 drop in each eye every 12 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Solution 0.09% (eg, Cequa): Adolescents ≥18 years: Ophthalmic: Instill 1 drop in each eye every 12 hours.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="cfa18650-2cd0-4887-9df4-fc232b2427cb">Vernal keratoconjunctivitis, severe</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Vernal keratoconjunctivitis, severe:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Treatment:</p>
<p style="text-indent:-2em;margin-left:6em;">Ophthalmic emulsion 0.1% (eg, Verkazia): Children ≥4 years and Adolescents: Ophthalmic: Instill 1 drop in affected eye(s) 4 times daily until signs/symptoms resolve. Treatment may be reinitiated if there is a recurrence (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30593775','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30593775','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Ophthalmic emulsion 0.05% (eg, Restasis): Limited data available: Children ≥5 years and ≤14 years: Ophthalmic: Instill 1 drop in affected eye(s) 4 times daily. Dosing based on experience from a prospective trial (n=54; age: 9.6 ± 2.5 years [range: 5 to 14 years]) and a case series (n=6; age: 6 to 14 years) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18991035','lexi-content-ref-17893529']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18991035','lexi-content-ref-17893529'])">Ref</a></span>). Higher concentrations of cyclosporine have also shown efficacy in clinical trials (1% and 2%); however, those formulations have a different vehicle and are not commercially available in the United States (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23625179']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23625179'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Prevention: Limited data available:</p>
<p style="text-indent:-2em;margin-left:6em;">Ophthalmic emulsion 0.05% (eg, Restasis): Children ≥6 years and Adolescents: Ophthalmic: Instill 1 drop in affected eye(s) twice daily; dosing based on a blinded, comparative (ketotifen) crossover trial in 34 pediatric patients (mean age: 14 ± 7 years) with severe but stable vernal keratoconjunctivitis; over a 2-year period, cyclosporine showed a statistically significant reduction in number of recurrences or flare-up compared to ketotifen; both drugs were considered to be well-tolerated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21868078']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21868078'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51090478"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, dosage adjustment unlikely necessary due to low systemic absorption.</p></div>
<div class="block dohp drugH1Div" id="F51090479"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, dosage adjustment unlikely necessary due to low systemic absorption.</p></div>
<div class="block adr drugH1Div" id="F8012584"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Ophthalmic: Burning sensation of eyes (17%), eye pain (1% to 22%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary tract infection (1% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache (1% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blepharitis (1% to 5%), blurred vision (1% to 5%), conjunctival hyperemia (1% to 6%), decreased visual acuity (3% to 5%), epiphora (1% to 5%), eye discharge (1% to 5%), eye discomfort (≤6%), eye irritation (1% to 5%), eye pruritus (1% to 8%), foreign body sensation of eye (≤6%), ocular hyperemia (4%), stinging of eyes (1% to 5%), visual disturbance (1% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (5%), upper respiratory tract infection (2%)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing: Hypersensitivity: Angioedema, hypersensitivity reaction</p></div>
<div class="block coi drugH1Div" id="F8012551"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to cyclosporine or any component of the formulation.</p>
<p style="text-indent:-2em;margin-left:4em;">Vevye: There are no contraindications listed in the US labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling):</p>
<p style="text-indent:-2em;margin-left:4em;">Cequa, Verkazia: Patients with active or suspected ocular or periocular infection; patients with ocular or periocular malignancies or premalignant conditions.</p>
<p style="text-indent:-2em;margin-left:4em;">Restasis, Restasis multidose: Patients with active ocular infections.</p></div>
<div class="block war drugH1Div" id="F8012562"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Contact lens wearers: Remove contact lens prior to administration and wait 15 minutes before reinserting.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues: </i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: To avoid contamination, do not touch vial tip to eyelids or other surfaces.</p></div>
<div class="block foc drugH1Div" id="F8012680"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Emulsion, Ophthalmic [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Restasis: 0.05% (30 ea, 60 ea) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Restasis MultiDose: 0.05% (1.5 mL [DSC], 5.5 mL) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Verkazia: 0.1% (120 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.05% (30 ea, 60 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Ophthalmic: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Vevye: 0.1% (2 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Ophthalmic [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cequa: 0.09% (60 ea) [contains peg-40 hydrog castor oil(cremophor rh40)]</p></div>
<div class="block geq drugH1Div" id="F8012548"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F8012682"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Emulsion</b> (cycloSPORINE Ophthalmic)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.05% (per each): $12.27</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Emulsion</b> (Restasis MultiDose Ophthalmic)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.05% (per mL): $140.87</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Emulsion</b> (Restasis Ophthalmic)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.05% (per each): $12.91</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Emulsion</b> (Verkazia Ophthalmic)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.1% (per each): $18.31</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Cequa Ophthalmic)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.09% (per each): $11.74</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Vevye Ophthalmic)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.1% (per mL): $462.00</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52869098"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Emulsion, Ophthalmic: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Restasis: 0.05% (0.4 mL) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Restasis MultiDose: 0.05% (5.5 mL) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Verkazia: 0.1% (0.3 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.05% (0.4 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Ophthalmic: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cequa: 0.09% (0.25 mL) [contains peg-40 hydrog castor oil(cremophor rh40)]</p></div>
<div class="block adm drugH1Div" id="F8012664"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Ophthalmic:</b> Administer single-use vials immediately after opening; discard remaining contents after use. Remove contact lenses prior to instillation of drops; may be reinserted 15 minutes after administration. To avoid contamination, do not touch bottle tip or vial tip to eyelids or other surfaces.</p>
<p style="text-indent:-2em;margin-left:2em;">Cequa: May be used with lubricant eye drops; allow 15-minute interval between products.</p>
<p style="text-indent:-2em;margin-left:2em;">Restasis: Prior to use, invert bottle or vial several times to obtain a uniform emulsion. Prime multidose bottle for first-time use by squeezing 2 drops onto a tissue (do not let bottle tip touch tissue). May be used with lubricant eye drops; allow 15-minute interval between products.</p>
<p style="text-indent:-2em;margin-left:2em;">Verkazia: Gently shake vial several times prior to use. Separate other eye products by at least 10 minutes; administer 10 minutes before using any eye gel, ointment, or viscous eye drops.</p>
<p style="text-indent:-2em;margin-left:2em;">Vevye: Separate other eye products by at least 15 minutes.</p></div>
<div class="block admp drugH1Div" id="F52614138"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Ophthalmic: For ophthalmic use only. Administer immediately after opening single-use vial; discard remaining contents after use. Avoid contact of vial tip with skin or eye; remove contact lenses prior to administration; lenses may be inserted 15 minutes after instillation.</p>
<p style="text-indent:-2em;margin-left:2em;">Emulsion 0.05% (eg, Restasis): Prior to use, invert vial several times to obtain a uniform emulsion. For multidose container, prime bottle for first-time use by squeezing 2 drops onto a tissue; do not let bottle tip touch tissue.</p>
<p style="text-indent:-2em;margin-left:2em;">Emulsion 0.1% (eg, Verkazia): Supplied in a single-dose container containing adequate volume to treat both eyes; discard immediately after use. Shake prior to use. Separate other eye products by at least 10 minutes; administer 10 minutes before using any eye gel, ointment, or viscous eye drops.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Missed dose:</i> Skip missed dose and administer next scheduled dose.</p></div>
<div class="block hazard drugH1Div" id="F49130961"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 2]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage. NIOSH recommends double gloving, a protective gown, and (if liquid that could splash) eye/face protection for administration of a topical product (NIOSH 2016). Assess risk to determine appropriate containment strategy (USP-NF 2017).</p></div>
<div class="block use drugH1Div" id="F8012549"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dry eye disease:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Cequa: Increase tear production in patients with keratoconjunctivitis sicca.</p>
<p style="text-indent:-2em;margin-left:4em;">Restasis: Increase tear production when suppressed tear production is presumed to be due to keratoconjunctivitis sicca-associated ocular inflammation (in patients not already using topical anti-inflammatory drugs or punctal plugs).</p>
<p style="text-indent:-2em;margin-left:4em;">Vevye: Treatment of the signs and symptoms of dry eye disease.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Vernal keratoconjunctivitis (Verkazia):</b> Treatment of vernal keratoconjunctivitis in children and adults.</p></div>
<div class="block mst drugH1Div" id="F8012532"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">CycloSPORINE may be confused with cycloPHOSphamide, Cyklokapron, cycloSERINE, voclosporin</p>
<p style="text-indent:-2em;margin-left:4em;">Restasis may be confused with Refresh Celluvisc</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes that have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299110"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F8012590"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block pri drugH1Div" id="F10923624"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Serum concentrations are below the limit of detection (&lt;0.1 ng/mL) following ophthalmic use; fetal exposure following ophthalmic administration is not expected.</p></div>
<div class="block brc drugH1Div" id="F10923625"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">Cyclosporine is present in breast milk following oral administration (refer to the Cyclosporine [Systemic] monograph for additional information). Serum concentrations are below the limit of detection (&lt;0.1 ng/mL) following ophthalmic use. According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should take into account the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p></div>
<div class="block phk drugH1Div" id="F8012626"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">Absorption: Cequa, Restasis: Serum concentrations were below the quantitation limit of 0.1 ng/mL; Verkazia: Maximum serum concentration 0.67 ng/mL.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F10961967"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Cipos | Closporil | Inmunosporin | Lacrinmune</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Sandimmun | Sandimmun n. | Sandimmun neoral</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Cyclorin | Cyporin | Sporium | Sporium max</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Ciclosporin eye drops (ii) | Cyclosporin | Sai si ping</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Modusik a ofteno | Sandimmun neoral</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Sandimmun</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Verkazia</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Ciclograft | Ikervis</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Aurosporine | Cyclisis pf | Cyclodrop | Cyclomune | Cyclotears | Hyclo | Hydroeyes hs | Nano eye | NanoTears | Porin tears</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Cipol n | Cyporin n | Cypriem | Eyeporine | Gengraf | Lysporine | N sporine | Restaporin | Restasis | Sandimmun neoral</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Sandimmun</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Daeqos | Modusik a ofteno | Neolem | Supremunn s | Zaven me</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Neoral | Sandimmune</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Modusik a ofteno</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Cyclo | Cylor | Ristases | Sporin | Xiclone</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Restasis</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Restasis</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Ilast | Zaven me</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Depores</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Depores free | Ocurin</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Icervis</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Ilast | Modusik a ofteno</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USPNF.1">
<a name="USPNF.1"></a>&lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 40-NF 35). Rockville, MD: United States Pharmacopeia Convention; 2017:83-102.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3960626">
<a name="3960626"></a>Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics.</i> 1986;77(4):593-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclosporine-ciclosporin-ophthalmic-drug-information/abstract-text/3960626/pubmed" id="3960626" target="_blank">3960626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6423951">
<a name="6423951"></a>Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product.<i> MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclosporine-ciclosporin-ophthalmic-drug-information/abstract-text/6423951/pubmed" id="6423951" target="_blank">6423951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cequa.1">
<a name="Cequa.1"></a>Cequa (cyclosporine) [prescribing information]. Cranbury, NJ: Sun Pharmaceutical Industries Inc; December 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CequaCAN.1">
<a name="CequaCAN.1"></a>Cequa (cyclosporine) [product monograph]. Brampton, Ontario, Canada: Sun Pharma Canada Inc; January 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12534540">
<a name="12534540"></a>Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclosporine-ciclosporin-ophthalmic-drug-information/abstract-text/12534540/pubmed" id="12534540" target="_blank">12534540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18991035">
<a name="18991035"></a>Keklikci U, Soker SI, Sakalar YB, Unlu K, Ozekinci S, Tunik S. Efficacy of topical cyclosporin A 0.05% in conjunctival impression cytology specimens and clinical findings of severe vernal keratoconjunctivitis in children. <i>Jpn J Ophthalmol</i>. 2008;52(5):357-362.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclosporine-ciclosporin-ophthalmic-drug-information/abstract-text/18991035/pubmed" id="18991035" target="_blank">18991035</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21868078">
<a name="21868078"></a>Lambiase A, Leonardi A, Sacchetti M, Deligianni V, Sposato S, Bonini S. Topical cyclosporine prevents seasonal recurrences of vernal keratoconjunctivitis in a randomized, double-masked, controlled 2-year study. <i>J Allergy Clin Immunol</i>. 2011;128(4):896-897.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclosporine-ciclosporin-ophthalmic-drug-information/abstract-text/21868078/pubmed" id="21868078" target="_blank">21868078</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30593775">
<a name="30593775"></a>Leonardi A, Doan S, Amrane M, et al. A randomized, controlled trial of cyclosporine A cationic emulsion in pediatric vernal keratoconjunctivitis: the VEKTIS study. <i>Ophthalmology</i>. 2019;126(5):671-681.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclosporine-ciclosporin-ophthalmic-drug-information/abstract-text/30593775/pubmed" id="30593775" target="_blank">30593775</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10985636">
<a name="10985636"></a>Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclosporine-ciclosporin-ophthalmic-drug-information/abstract-text/10985636/pubmed" id="10985636" target="_blank">10985636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17893529">
<a name="17893529"></a>Ozcan AA, Ersoz TR, Dulger E. Management of severe allergic conjunctivitis with topical cyclosporin a 0.05% eyedrops. <i>Cornea</i>. 2007;26(9):1035-1038.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclosporine-ciclosporin-ophthalmic-drug-information/abstract-text/17893529/pubmed" id="17893529" target="_blank">17893529</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Restasis.1">
<a name="Restasis.1"></a>Restasis (cyclosporine) [prescribing information]. Irvine, CA: Allergan Inc; received July 20, 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-RestasisCAN.1">
<a name="RestasisCAN.1"></a>Restasis (cyclosporine) ophthalmic emulsion [product monograph]. Saint-Laurent, Quebec, Canada: AbbVie Corporation; August 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-RestasisMultidose.1">
<a name="RestasisMultidose.1"></a>Restasis Multidose (cyclosporine) [prescribing information]. Irvine, CA: Allergan Inc; October 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Restasis.4">
<a name="Restasis.4"></a>Restasis Multidose (cyclosporine) [product monograph]. St-Laurent, Quebec, Canada: AbbVie Corporation; February 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7746084">
<a name="7746084"></a>Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclosporine-ciclosporin-ophthalmic-drug-information/abstract-text/7746084/pubmed" id="7746084" target="_blank">7746084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIOSH.1">
<a name="NIOSH.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Verkazia.1">
<a name="Verkazia.1"></a>Verkazia (cyclosporine) [prescribing information]. Emeryville, CA: Santen Incorporated; June 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-VerkaziaCAN.1">
<a name="VerkaziaCAN.1"></a>Verkazia (cyclosporine) [product monograph]. Emeryville, CA: Santen Incorporated; December 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Vevye.1">
<a name="Vevye.1"></a>Vevye (cyclosporine) [prescribing information]. Greensboro, NC: Harrow Eye, LLC; November 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23625179">
<a name="23625179"></a>Vichyanond P, Kosrirukvongs P. Use of cyclosporine A and tacrolimus in treatment of vernal keratoconjunctivitis.<i> Curr Allergy Asthma Rep</i>. 2013;13(3):308-314.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclosporine-ciclosporin-ophthalmic-drug-information/abstract-text/23625179/pubmed" id="23625179" target="_blank">23625179</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9093 Version 250.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
